Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 13/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5597158 | 0.98 | EPHX1 (0.66) | EPHX1SMN1; SMN2RAB9ANPC1ALDH1A1 | |
| SCHEMBL5596388 | 0.96 | EPHX1 (0.58) | EPHX1SMN1; SMN2RAB9ANPC1ALDH1A1 | |
| SCHEMBL5597219 | 0.92 | EPHX1 (0.53) | EPHX1SMN1; SMN2ALDH1A1EPHX2 | |
| SCHEMBL5597218 | 0.89 | EPHX1 (0.64) | EPHX1SMN1; SMN2RAB9ANPC1ALDH1A1 | |
| SCHEMBL5597213 | 0.87 | EPHX1 (0.67) | EPHX1SMN1; SMN2RAB9ANPC1ALDH1A1 | |
| SCHEMBL5596623 | 0.85 | EPHX1 (0.59) | EPHX1SMN1; SMN2ALDH1A1EPHX2 | |
| SCHEMBL5596837 | 0.84 | EPHX1 (0.57) | EPHX1SMN1; SMN2RAB9ANPC1ALDH1A1 | |
| SCHEMBL482520 | 0.82 | EPHX1 (0.60) | EPHX1SMN1; SMN2RAB9ANPC1ALDH1A1 | |
| SCHEMBL5596644 | 0.81 | EPHX1 (0.54) | EPHX1SMN1; SMN2ALDH1A1 | |
| SCHEMBL8653001 | 0.81 | EPHX1 (0.63) | EPHX1SMN1; SMN2RAB9ANPC1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1829876-A1 | NITROGENEOUS TRICYCLIC COMPOUND | Asahi Kasei Pharma Corporation (JP) | 2007-09-05 | — | — | EP | disclosed |
| US-20060247266-A1 | Nitrogen-containing tricyclic compounds | ASAHI KASEI PHARMA CORPORATION (JP) | 2006-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247266-A1 | Nitrogen-containing tricyclic compounds | MYO1B, CHRM1, MYL12A | EPHX1 4424/4885SMN1; SMN2 2149/4885RAB9A 1808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.